While the development of genetic therapies promises to revolutionize medicine, many challenges remain before this emerging area of therapeutics can be fully realized. Senda Biosciences is tapping into a world of naturally-existing nanoparticles to address these challenges. It is creating new classes of programmable medicines by performing deep molecular profiling and advanced analytics on an expansive world of natural nanoparticles and what it calls information molecules, such as mRNA. We spoke to Senda CEO Guillaume Pfefer and Senda Chief Platform Officer Stuart Milstein, about its platform technology, how it is building an atlas of natural nanoparticles, and how its work is leading to a pipeline of programmable medicines.

Ver todos los episodios